GlobeNewsWire
03 Jun 2026, 13:45 UTC · 23w ago
MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion
Impact · against what's priced in
MAIA Biotechnology's FDA clearance to open U.S. enrollment for its Phase 2 THIO-101 trial expansion provides a critical regulatory bridge toward potential Accelerated Approval. This development, combined with updated manufacturing protocols and an ongoing Phase 3 trial, significantly derisks the lead candidate's path to the U.S. market.
- MAIA+0.60
No priced-in read yet





